Mipasetamab uzoptirine

Highest phase reached
Phase 1
www.ebi.ac.uk
Drug type
Antibody drug conjugate
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 1
www.ebi.ac.uk

Drug type
Antibody drug conjugate
www.ebi.ac.uk
Drug name
Mipasetamab uzoptirine
www.ebi.ac.uk

  • adct 601
  • ADCT-601
  • immunoglobulin g1 anti human receptor tyrosine kinase axl human mus musculus monoclonal 1h12 gamma 1 chain disulfide with human mus musculus monoclonal 1h12 kappa chain dimer 302 302 bis n o 2 acetylamino 6 azido 2 6 dideoxy beta d galactopyranosyl 1 4 o 6 deoxy alpha l galactopyranosyl 1 6 2 acetylamino 2 deoxy beta d glucopyranosyl l asparagine click reaction product with n 10 10 dioxido 1 12 dioxo 14 1 alpha 8 alpha 9 beta bicyclo 6 1 0 non 4 yn 9 yl 3 6 13 trioxa 10 thia 9 11 diazatetradec 1 yl l valyl n 4 11s 11as 8 5 11as 5 11a dihydro 7 methoxy 2 methyl 5 oxo 1h pyrrolo 2 1 c 1 4 benzodiazepin 8 yl oxy pentyl oxy 11 11a dihydro 11 hydroxy 7 methoxy 2 methyl 5 oxo 1h pyrrolo 2 1 c 1 4 benzodiazepin 10 5h yl carbonyl oxy methyl phenyl l alaninamide
  • immunoglobulin g1 kappa anti homo sapiens axl axl receptor tyrosine kinase tyrosine protein kinase receptor ufo humanized monoclonal antibody conjugated to the pyrrolobenzodiazepine pbd dimer sg3199 mipasetamab uzoptirine
  • immunoglobulin g1 kappa anti homo sapiens tyrosine protein kinase receptor ufo axl oncogene ec 2 7 10 1 humanized monoclonal antibody conjugated to the pyrrolobenzodiazepine pdb dimer sg3199 gamma 1 heavy chain humanized 1 451 vh humanized homo sapiens ighv3 30 03 93 ighd ighj4 01 92 8 8 15 1 122 homo sapiens ighg1 03 ch1 r97 k 219 ch3 k107 del 452 123 451 225 215 disulfide with kappa light chain humanized 1 215 humanized v kappa homo sapiens igkv3 11 01 84 igkj4 01 91 7 3 9 1 108 homo sapiens igkc 01 109 215 dimer 231 231 234 234 bisdisulfide produced in chinese cho cells glycoform alfa conjugated on the two glycoengineered asn 302 and asn 302 via a spacer and cleavable valyl alanyl linker to the cytotoxic pyrrolobenzodiazepine pbd dimer sg3199
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS AXL (AXL RECEPTOR TYROSINE KINASE, TYROSINE-PROTEIN KINASE RECEPTOR UFO)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PBD) DIMER, SG3199 (MIPASETAMAB UZOPTIRINE)
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TYROSINE-PROTEIN KINASE RECEPTOR UFO (AXL ONCOGENE; EC=2.7.10.1)); HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER, SG3199; .GAMMA.1 HEAVY CHAIN HUMANIZED (1-451) (VH HUMANIZED (HOMO SAPIENS IGHV3-30*03 (93%)-(IGHD)-IGHJ4*01 (92%)) (8.8.15) (1-122) HOMO SAPIENS IGHG1*03 (CH1(R97>K(219)), CH3(K107>DEL(452))) (123-451)), (225-215')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED (1'-215') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV3-11*01 (84%)-IGKJ4*01 (91%))(7.3.9) (1'-108')-HOMO SAPIENS IGKC*01 (109'-215')); DIMER (231-231'':234-234'')-BISDISULFIDE, PRODUCED IN CHINESE CHO CELLS, GLYCOFORM ALFA; CONJUGATED ON THE TWO GLYCOENGINEERED ASN-302 AND ASN-302'', VIA A SPACER AND CLEAVABLE VALYL-ALANYL LINKER, TO THE CYTOTOXIC PYRROLOBENZODIAZEPINE (PBD) DIMER, SG3199
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN RECEPTOR TYROSINE KINASE AXL) (HUMAN-MUS MUSCULUS MONOCLONAL 1H12 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL 1H12 .KAPPA.-CHAIN, DIMER, 302,302'-BIS(N-(O-2-(ACETYLAMINO)-6-AZIDO-2,6-DIDEOXY-.BETA.-D-GALACTOPYRANOSYL-(1->4)-O-(6-DEOXY-.ALPHA.-L-GALACTOPYRANOSYL-(1->6))-2-(ACETYLAMINO)-2-DEOXY-.BETA.-D-GLUCOPYRANOSYL)-L-ASPARAGINE), CLICK REACTION PRODUCT WITH N-(10,10-DIOXIDO-1,12-DIOXO-14-((1.ALPHA.,8.ALPHA.,9.BETA.)-BICYCLO(6.1.0)NON-4-YN-9-YL)-3,6,13-TRIOXA-10-THIA-9,11-DIAZATETRADEC-1-YL)-L-VALYL-N-(4-(((((11S,11AS)-8-((5-(((11AS)-5,11A-DIHYDRO-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-8-YL)OXY)PENTYL)OXY)-11,11A-DIHYDRO-11-HYDROXY-7-METHOXY-2-METHYL-5-OXO-1H-PYRROLO(2,1-C)(1,4)BENZODIAZEPIN-10(5H)-YL)CARBONYL)OXY)METHYL)PHENYL)-L-ALANINAMIDE
  • mipasetamab uzoptirine
  • Mipasetamab uzoptirine
  • mipasetamab uzoptirine [INN]
  • MIPASETAMAB UZOPTIRINE [USAN]
  • Mipasetamab uzoptirine [WHO-DD]
  • mipasetamab uzoptirine inn
  • mipasetamab uzoptirine usan
  • mipasetamab uzoptirine who dd

CAS registry numbers
  • 2304799-73-1
ChEMBL ID
CHEMBL5095300
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 71KV7F609O

First in class
No
Orphan designation
No

Drug name stem
-mab

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    1
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005070
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Glycosylation sites (N)
    Sequence
    Asn-302 $ Asn-302''''
  • Component
    Light chain
    Type
    Protein
    Sequence
    EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    X1VQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYX2STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
  • Component
    Glycosylation sites (N)
    Sequence
    Asn-302 $ Asn-302''
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-89' $ 23'''-89''' $ 135'-195' $ 135'''-195''' $ 149-205 $ 149''-205''' $ 215'-225 $ 215'''-225'' $ 231-231'' $ 234-234'' $ 266-326 $ 266''-326'' $ 372-430 $ 372''-430''

Related records

Trials (2)

In development for (1)